prednisolone has been researched along with Optic Atrophy, Hereditary, Leber in 2 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Optic Atrophy, Hereditary, Leber: A maternally linked genetic disorder that presents in mid-life as acute or subacute central vision loss leading to central scotoma and blindness. The disease has been associated with missense mutations in the mtDNA, in genes for Complex I, III, and IV polypeptides, that can act autonomously or in association with each other to cause the disease. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim/, MIM#535000 (April 17, 2001))
| Excerpt | Relevance | Reference |
|---|---|---|
| " None of the nine patients had local or systemic adverse events related to the vector during the 9-month follow-up period." | 2.82 | Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy. ( Chen, C; Dong, XY; He, H; Hu, WK; Li, B; Ma, SQ; Pei, H; Wan, X; Wang, DW; Yang, S; Zhang, G; Zhao, MJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heidari, E | 1 |
| Rasoulinezhad, M | 1 |
| Pak, N | 1 |
| Reza Ashrafi, M | 1 |
| Heidari, M | 1 |
| Banwell, B | 1 |
| Garshasbi, M | 1 |
| Reza Tavasoli, A | 1 |
| Wan, X | 1 |
| Pei, H | 1 |
| Zhao, MJ | 1 |
| Yang, S | 1 |
| Hu, WK | 1 |
| He, H | 1 |
| Ma, SQ | 1 |
| Zhang, G | 1 |
| Dong, XY | 1 |
| Chen, C | 1 |
| Wang, DW | 1 |
| Li, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy[NCT03153293] | Phase 2/Phase 3 | 159 participants (Actual) | Interventional | 2017-12-27 | Active, not recruiting | ||
| Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy[NCT01267422] | 9 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months[NCT03428178] | 120 participants (Actual) | Interventional | 2018-01-08 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01267422)
Timeframe: Up to 3 years
| Intervention | mmHg (Mean) |
|---|---|
| IOP Before Treatment | 14 |
| IOP After Treatment | 16 |
The mean of Neutralizing antibody assay of 8 patients before and after treatment (NCT01267422)
Timeframe: up to 3 years
| Intervention | titer (Mean) |
|---|---|
| The Mean of Neutralizing Antibody Assay Before Treatment | 0.9221 |
| The Mean of Neutralizing Antibody Assay After Treatment | 0.8723 |
Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment (NCT01267422)
Timeframe: Up to 3 years
| Intervention | Micrometer (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Average RNFL Thickness After Treatment | 46.7813 | 47.9688 |
| Average RNFL Thickness Before Treatment | 47.3125 | 50.1875 |
MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years
| Intervention | dB (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Mean MD After Treatment | -23.813 | -23.427 |
| Mean MD Before Treatment | -29.377 | -28.701 |
VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years
| Intervention | Percentage of normal (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Mean VFI After Treatment | 28 | 25 |
| Mean VFI Before Treatment | 11 | 10.5 |
The mean percentage of CD3+/CD4+/CD8+ test before and after treatment (NCT01267422)
Timeframe: up to 6 months
| Intervention | Percentage of total cells (Mean) | ||
|---|---|---|---|
| Values of CD3+ | Values of CD4+ | Values of CD8+ | |
| The Mean Percentage of CD3+/CD4+/CD8+ After Treatment | 53 | 20 | 13 |
| The Mean Percentage of CD3+/CD4+/CD8+ Before Treatment | 51 | 26 | 20 |
(NCT01267422)
Timeframe: Up to 3 years
| Intervention | logMAR (Mean) | ||||
|---|---|---|---|---|---|
| before treament | 1 months after treament | 3 months after treament | 6 months after treament | 9 months after treament | |
| BCVA of Treated Eyes | 1.69 | 1.58 | 1.38 | 1.23 | 1.27 |
| BCVA of Un-treated Eyes | 1.40 | 1.36 | 1.31 | 1.20 | 1.23 |
1 trial available for prednisolone and Optic Atrophy, Hereditary, Leber
| Article | Year |
|---|---|
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
1 other study available for prednisolone and Optic Atrophy, Hereditary, Leber
| Article | Year |
|---|---|
Defective complex III mitochondrial respiratory chain due to a novel variant in CYC1 gene masquerades acute demyelinating syndrome or Leber hereditary optic neuropathy.
Topics: Amino Acid Substitution; Base Sequence; Brain; Child; Computer Simulation; Electron Transport; Elect | 2021 |